Vocabria

Vocabria Warnings

cabotegravir

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig

Marketer:

GlaxoSmithKline
Full Prescribing Info
Warnings
Suspension for injection: Risk of resistance following treatment discontinuation: To minimise the risk of developing viral resistance it is essential to adopt an alternative, fully suppressive antiretroviral regimen no later than one month after the final injection of Vocabria when dosed monthly and no later than two months after the final injection of Vocabria when dosed every 2 months.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in